HC Wainwright Reiterates “Buy” Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reaffirmed their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report issued on Wednesday, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.08) EPS, FY2025 earnings at ($0.96) EPS and FY2026 earnings at ($0.43) EPS.

A number of other research analysts also recently issued reports on the company. Royal Bank of Canada reiterated an outperform rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an outperform rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Karyopharm Therapeutics has an average rating of Moderate Buy and a consensus price target of $4.80.

Karyopharm Therapeutics Trading Down 3.4 %

NASDAQ:KPTI traded down $0.03 during mid-day trading on Wednesday, reaching $0.81. The company’s stock had a trading volume of 329,845 shares, compared to its average volume of 1,487,917. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The firm’s fifty day moving average price is $0.93 and its two-hundred day moving average price is $1.12. The stock has a market cap of $100.94 million, a P/E ratio of -0.64 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million for the quarter, compared to analysts’ expectations of $35.02 million. Analysts predict that Karyopharm Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 360,744 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $1.00, for a total value of $360,744.00. Following the completion of the sale, the director now owns 11,209 shares of the company’s stock, valued at $11,209. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 1,279,081 shares of company stock valued at $1,237,898. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at approximately $339,000. Panagora Asset Management Inc. acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $197,000. Acadian Asset Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth approximately $167,000. Monashee Investment Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $115,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Karyopharm Therapeutics by 6.5% in the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after acquiring an additional 108,286 shares during the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).